However, despite evidence demonstrating the contribution of myostatin to the progression of atherosclerosis in humans [9] and mice [8,10], no clinical study, to our knowledge, has investigated the relationship between myostatin levels and cardiovascular events in patients with CKD. This evidence concerns the gene MSTN and chronic kidney disease.